REGN
Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN
Article Summary
HOLD- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) suffered significant losses after a major news event, prompting Robbins LLP to urge investors with significant losses to contact the firm for information about their rights against Regeneron Pharmaceuticals,.
- The firm emphasized that investors should focus on the specific news event rather than background details surrounding the company's financial performance.
- Investors are urged to contact Robbins LLP if they believe they may have lost significant amounts of money investing in REGN.
- The company continues to face regulatory and clinical challenges related to its ongoing regulatory and commercialization efforts.
- Investors should assess whether they still have any legal exposure to the company following the news.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 5.9% | 25% | 35.0 ptsBelow Screener (5.9%) - Weak growth |
| EPS Growth Next 5Y ? | 11.2% | 25% | 35.0 ptsBelow Screener (11.2%) - Modest outlook |
| Target Price Upside ? | 26.5% | 20% | 75.0 ptsSignificant Upside (26.5%) - Target: $825.08 vs Current: $652.03 |
| Gross Margin % ? | 80.9% | 15% | 100.0 ptsExceptional (80.9%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -20.6% | 15% | 40.0 ptsMild Pullback (-20.6%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About REGN
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
- The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
- It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
- It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency.
- Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies.
- It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies.
- The company was incorporated in 1988 and is based in Tarrytown, New York.